This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
On Saturday, researchers at the Children’s Hospital of Philadelphia (CHOP) have announced that they developed and launched a new bioinformatics software tool called CancerVar (cancer variant interpretation). Millions of somatic cancer variants have been identified due to precision medicine and next-generation sequencing (NGS).
Making strategic decisions when designing the protocol, such as including biomarkers like programmed death ligand-1 protein expression to guide the use of immune checkpoint inhibitors during treatment, can better assure safety and efficacy.
While there may be just under 20,000 confirmed protein coding genes, it turns out that much of the genome outside of these genes is also important in regulating how the genome is controlled. Bioinformatic techniques are then used to piece together the reads into a continuous genomic sequence by aligning them to the reference human genome.
This impressive growth can be attributed to Fulgent’s distinctive chemistries and advanced proprietary bioinformatics pipeline, which have been instrumental in fueling the company’s rapid advancement in recent years. Alpine Immune Sciences has recently announced an augmentation in its R&D investment. million and $38.8 million and $33.9
Capturing how RNA polymerase enzymes kick off transcription On scales too small for our eyes to see, the business of life happens through the making of proteins, which impart to our cells both structure and function.
Recent advances in multi-omics approaches, including genomics, transcriptomics, proteomics, metabolomics, cytometry and imaging, in combination with bioinformatics and biostatistics, have been translated into several popular bioanalytical platforms, such as next-generation sequencing (NGS), single-cell analysis, flow cytometry and mass spectrometry.
Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. The cfDNA that originates from tumors is called circulating tumor DNA (ctDNA). Optimal methods for bioinformatic analysis are still needed. percent show less reliability).
I actually think neuroscience is going to heat up in 2021,” said Ben Zeskind , co-founder and CEO of Immuneering , which is using bioinformatics and computational biology to develop new drugs in this space, along with oncology and immuno-oncology. Moving on From the Amyloid Hypothesis. “I A Whole New ‘Science Matters’ Perspective . “I
Protein therapeutics have completely revolutionized the healthcare segment, greatly influencing the study and treatment of human diseases by conferring precise targeting ability to therapeutic modalities. Considering their vast potential, close to 50% of the top selling drugs in 2023 were protein therapeutics.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content